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CEA, CA19-9 and CA50 are tumour associated antigens defined by monoclonal antibodies which have
been raised against adenocarcinoma cell lines. The aim of this study was to determine whether their
combined use could improve diagnostic accuracy in patients with primary and secondary liver tumours.
An immunoradiometric assay was used for the detection of CEA_ and CA19-9 and the Delfia system for
CA50. Serum was collected from 65 normal subjects, 40 with hepatobiliary carcinoma (26 primary, 14
secondary) and 17 with benign hepatobiliary disease. The cut-off levels were calculated as the mean of
the control group plus 2 standard deviations. All three antibodies contributed to improving the correct
classification of secondary liver tumours (multivariant discriminant analysis p< 0.05), but only CA19-9
and CA50 contributed to the diagnosis of primary liver tumours (multivariant analysis p< 0.05). The
diagnostic accuracy versus benign disease was 81% for primary carcinoma and 91% for secondary
carcinoma. Combined use of CEA, CA19-9 and CA50 helps to differentiate benign from malignant
hepatobiliary disease.
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INTRODUCTION
In the last three decades hepatobiliary surgery has progressed to become a distinct
sub-speciality, with a mortality rate for hepatic resection below 5% 1’2.
Hepatectomy may be suitable for primary malignant tumours (hepatocellular
carcinoma, cholangiocarcinoma), but in the western world these are outnumbered
by liver metastases, 70% of which originate from colorectal primary lesions3. Since
most patients with colorectal secondaries are asymptomatic at first, a sensitive test
is required to diagnose them early enough for surgical treatment still to be feasible;
determination of high levels of carcino-embryonic antigen (CEA) in the serum is
one such possibility4. At present resection of colorectal liver metases is only
possible in 30-40% of patients, 5’6 but up to 25% of these may be expected to
survive 5 years.
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Among primary hepatic malignancies, hepatocellular carcinoma (HCC) is
increasing in incidence,
7 but patients tend to present at a late stage with irresectable
lesions. For small lesions discovered even before the onset of symptoms, for
example by ultrasound scan or a raised alpha-feto protein (AFP) level, resection
could be curative. The other common primary liver tumour, cholangiocarcinoma,
has no associated tumour marker currently available8. Resection is only appropri-
ate for 10-30% of cholangiocarcinomas, but when possible it is the most effective
treatment8’9. Tumour markers may offer an opportunity for the detection of early
disease.
CEA, CA 19-9 and CA 50 assays are based on monoclonal antibodies raised
against human colorectal carcinoma cell lines1’11. Elevated serum levels have been
found in patients with gastrointestinal and other malignancies12’13’14. The present
study assesses the sensitivity and specificity of these three tumour markers in the
differential diagnoses of benign and malignant liver disease.
PATIENTS AND METHODS
Single serum samples were collected from 65 normal healthy control subjects, 40
patients with hepatobiliary carcinoma and 17 patients with benign hepatobiliary
disease (Table 1). Serum was stored at -20C until analysis. The primary hepatobi-
liary cancer group included 13 patients with cholangiocarcinoma, 12 with hepato-
cellular carcinoma and one with carcinoma of the gall bladder. The metastatic
group contained 12 colonic and 2 gastric primaries.
Table 1 Details of patients
Age (yr)
Patients n Median Range
Controls 65 42 8-98
Benign hepatobiliary disease 17 58 12-74
Primary liver malignancy 26 47 17-71
Secondary liver malignancy 14 53 17-78
comprising haemangioma (3), hydatid disease (3), sclerosing cholangitis (2), viral hepatitis (2) and one
each of simple cyst, portal hypertension, primary biliary cirrhosis, biliary stricture, choledocholithiasis,
cholangitis and hepatic sarcoid.
A commercial kit was used for the detection of CEA and CA 19-9. ELSA-CEA
is a solid-phase two-site immunoradiometric assay specific for CEA. Three monoc-
lonal antibodies are prepared against sterically remote antigenic sites on the CEA
molecule: two of them are coated on the ELSA solid phase, while the third one is
radiolabelled with 125 iodine and used as a marker. Following the formation of the
coated antibody-antigen-iodinated antibody sandwich, the unbound tracer is
removed by washing. The radioactivity bound to the ELSA is proportional to the
concentration of CEA present in the sample.
CIS ELSA CA 19-9TM is a solid phase (ELSA) immunoradiometric assay specific
for CA 19-9. ELSA coated with mouse monoclonal antibody to CA 19-9TM is
incubated with the sample. CA 19-9TM then binds the ELSA. The same monoclonalCEA, CA 19-9, CA50 IN LIVER DISEASE 25
anti CA 19-9TM then binds with ELSA. Unbound tracer is removed by washing.
The radioactivity bound to ELSA is proportional to the concentration of CA 19-9
in the sample.
CA50 was detected by the disassociation enhanced lanthamide fluorimmunoas-
say (DELFIA) technique (Stena Diagnostics, Sweden). The Delfia technique is a
solid-phase immunofluorometric assay based on a direct sandwich technique.
For each assay a cut-off level was calculated according to the mean value of the
control group plus two standard deviations as follows CA19-9 46 u/ml, CEA7/g/
ml, CA50 21 u/ml. Data obtained were studied with multivariant discriminant
analysis to produce a model (based on known normal and abnormal values) which
is a linear combination giving the widest discrimination between tested normal and
abnormal subjects.
RESULTS
Table 2 shows the number of patients and controls with ’positive’ tumour markers.
Of 40 patients with hepatobiliary cancer 18 (45%) had a CA 19-9 level above 46 u/
ml,, 22 (55%) had a CA50 level above 21 u/ml and 15 (48%) had a CEA level
above 7/tg/ml. To improve specificity we used multivariant discriminant analysis of
the combination of antibodies. The analysis showed a positive result with 53% of
the whole malignant group, none of the benign group and 8% of the control group.
All three antibodies contributed to the diagnostic accuracy for the whole malignant
group (80%) and for secondary tumours (91%) but only CA 19-9 and CA50
contributed to improved diagnostic accuracy in the primary group alone (81%)
(Figure 1, Table 4). Further breakdown of the primary malignant group shows that
CEA was never positive in patients with hepatocellular carcinoma (Table 3).
Table 2 Number of patients and controls with ’positive’ tumour markers (i.e., values above cut-off
level)
Combination of
n CA19-9 CA50 CEA all 3 markers
Controls 65 6 7 5 5
Benign 17 0 4 0 0
Primary 26 12 13 5 11
Secondary 14 6 9 10 10
Primary and 40 18 22 15 21
Secondary
i.e. Patients positive with multivariant discriminant analysis.
Table 3 Percentage positive in patients with primary and secondary liver malignancies
Combination of
CA19-9 CA50 CEA all three markers
Cholangiocarcinoma 62 62 38 54
(n= 14)
Hepatocellular carcinoma 25 42 0 25
(n 12)
Secondary carcinoma 43 64 71 71
(n= 14)26 M.E. LUCAROTTI ETAL.
Table 4 Sensitivity and specificity of markers in primary and secondary liver malignancy
Primary liver malignancy
CA19-9 CA50 CEA
Combination of
all three markers
Sensitivity (%) 46 50 19 42
Specificity (%) 93 87 94 94
Diagnostic accuracy (%) 81 78 76 81
Secondary liver malignancy
CA19-9 CA50 CEA
Combination of
all three markers
Sensitivity (%) 43 64 71 71
Specificity (%) 93 87 94 94
Diagnostic accuracy (%) 85 83 91 91
Primary and secondary liver malignancy
CA19-9 CA50 CEA
Combination of
all three markers
Sensitivity (%) 45 55 38 53
Specificity (%) 93 87 94 94
Diagnostic accuracy (%) 77 76 75 80
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Figure 1 Percentage of patients with positive tumour markers, using single and combined antibodies.CEA, CA 19-9, CA50 IN LIVER DISEASE 27
DISCUSSION
In this study the combination of antibodies was positive in 11 of 26 patients (42%)
with primary liver tumours and 10 of 14 patients (71%) with secondary liver
tumours, but in none of 17 patients with benign hepatobiliary diseases and only 5 of
65 (8%) normal controls. There was a slight gain in diagnostic accuracy, largely
because of greater specificity, when the combination antibodies was employed over
the single use of any one test. This combination technique could therefore have a
useful additive value to existing diagnostic methods in the screening of high risk
groups, for example asymptomatic patients with liver cirrhosis, or those with
potentially curative resection of colorectal carcinoma. Such a policy might help in
the early detection of liver tumours at an asymptomatic stage where surgical
resection could still be possible.
Although surgical removal remains the only treatment with any hope of long-
term survival in patients with liver cancer, the extent of the disease usually
precludes hepatic resection by the time symptoms become established15. Bismuth et
al. 16 reported an incidence of resection of 10% in symptomatic patients with
hepatocellular carcinoma with liver cirrhosis, and only one of 35 patients survived
more than two years. On the other hand, Yu, Tang and Zhou17 reported a 60%
five-year survival in patients with liver cirrhosis undergoing a comprehensive
screening programme for HCC at an asymptomatic stage. Thus screening of high
risk groups should be implemented, and the use of a tumour marker combination
complemented by AFP measurement and ultrasonography seems the best method
currently available.
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